The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 60 | — | 20.1x | Near average | |
Growth | 24 | 1.5% | 5.6% | Below average | |
Quality | 85 | 28.4% | 7.6% | Above average | |
Safety | 39 | 3.5x | 0.4x | Near average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Heron Therapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Heron Therapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
HRTX stock has recently experienced a negative shift in analyst sentiment, with Needham downgrading the stock from 'Buy' to 'Hold' in June 2026. Although the average price target remains stable at $6.67, this figure is currently based on coverage from only one analyst, indicating a significant decline in institutional research confidence and a lower level of analytical coverage compared to previous periods of broad participation.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.